Trial of Betalutin-Rituxan Combo as Second-line Follicular Lymphoma Therapy Poised to Launch in Norway
News
A Phase 1b trial evaluating a combination of Betalutin (177Lu-satetraxetan-lilotomab) and Rituxan (rituximab) as a second-line therapy for follicular lymphoma will begin soon in Norway following Nordic Nanovector receiving all necessary approvals. The trial, called Archer-1, ... Read more